This trial aims to investigate a new cancer medicine called xentuzumab together with exemestane (Aromasin) and everolimus (Afinitor) in women who have breast cancer that has spread. The main outcome that will be measured is how long the patients go without cancer growing.
Xentuzumab is a new medication that works by targeting certain molecules on cancer cells. It aims to stop cancer cells from growing. It has not been tested in combination with two other anti-cancer drugs, called everolimus and exemestane.
This trial aims to investigate the effectiveness of xentuzumab combined with everolimus and exemestane in women with advanced breast cancer. The main outcome that will be measured is survival without cancer growing or spreading.
Who are they looking for?
80 post-menopausal women with breast cancer that cannot have curative surgery or radiation. Patients must have adequate organ function.
Patients will not be included if they have a history of lung or heart disease, or if they already received chemotherapy for cancer that has spread, or radiotherapy within 4 weeks prior to the start of study treatment.
How will it work
The patients will be split into two groups. One group will be treated with everolimus and exemestane plus a placebo pill. The second group will be treated with everolimus and exemestane plus xentuzumab. The patients will not know what kind of treatment they are getting. Patients will be followed up to 3 years to evaluate survival without cancer growing and response to treatment.